Abstract
Objective: To identify and analyze the prevalence and causality of adverse drug reactions in pediatric patients with neurologic diseases. Methods: A population study was carried out with 33 pediatric patients diagnosed with neurologic diseases under treatment with psychoactive drugs. Results: 48 % of patients had adverse drug reactions. Thirty-six adverse events were identified, of which, most were associated to the use of magnesium valproate (39%), and followed by methylphenidate (22%), piracetam (17%), and topiramate (8%). The main identified adverse drug reactions were: caries, hyperplasia, loss of appetite, hypersalivation, insomnia and irritability.
References
Alomar MJ. Factors affecting the development of adverse drug reactions. SPJ. 2014; 22:83-94. https://doi.org/10.1016/j.jsps.2013.02.003
World Health Organization. (2020). The importance of pharmacovigilance- safety monitoring of medicinal products. Disponible en https://drive.google.com/file/d/1GvH-RDTDdzynjhqDZaKaA1z9OL1-af2w/view?usp=sharing
Telechea H, Speranza N, Lucas L, Giachetto G, Nanni L, Menchaca A. Reacciones adversas a medicamentos en una unidad de cuidados intensivos pediátrica. Farm Hosp. 2012;36:403-9. https://doi.org/10.1016/j.farma.2011.08.007
World Health Organization. (2020). World Health Organization model list of essential medicines for children: 7th list 2019. Disponible en https://drive.google.com/file/d/1lKSJ2uimUC1L8cDguPCrNSHJztmpuL1q/view?usp=sharing
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30: 239-45. https://doi.org/10.1038/clpt.1981.154
Secretaría de Salud. (2012). Norma Oficial Mexicana NOM-012-SSA3-2012, Que establece los criterios para la ejecución de proyectos de investigación para la salud en seres humanos. Disponible en https://dof.gob.mx/nota_detalle.php?codigo=5284148&fecha=04/01/2013.
Ismail AI, Sohn W, Tellez M, Amaya A, Sen A, Hasson H, et al. The International Caries Detection and Assessment System (ICDAS): an integrated system for measuring dental caries. Community Dent Oral Epidemiol. 2007;35:170-8. https://doi.org/10.1111/j.1600-0528.2007.00347.x
De Helsinki D. (2001). Ethical Principles for Medical Research Involving Human Subjects. Disponible en https://www.who.int/bulletin/archives/79(4)373.pdf.
Huiracocha L, Robalino G, Huiracocha M, García J, Pazán C, Angulo A. Retrasos del desarrollo psicomotriz en niños y niñas urbanos de 0 a 5 años: Estudio de caso en la zona urbana de Cuenca, Ecuador, Maskana. 2012;3(1):13-28. https://doi.org/10.18537/mskn.03.01.02
Beghi E, and Hesdorffer D. Prevalence of epilepsy - An unknown quantity. Epilepsia. 2014;55:963-7.
Arencibia ZB, Leyva AL, Peña YM, Reyes AG, Manzano EF, Choonara I. Pharmacovigilance in children in Camagüey Province, Cuba. Eur J Clin Pharmacol. 2012;68:1079-84.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents–assessment of adverse events in non‐randomised studies. Cochrane Database Syst Rev. 2018. DOI: 10.1002/14651858.CD012069.pub2
Zoega H, Furu K, Halldorsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: a population‐based comparison study. Acta Psychiatr Scand. 2011;123:360-7. https://doi.org/10.1111/j.1600-0447.2010.01607.x
Spectrum: Autism Research News. (2020). Risperidone use in children with autism carries heavy risks. Disponible en https://www.spectrumnews.org/news/risperidone-use-in-children-with-autism-carries-heavy-risks/
Passos IA, Sampaio FC, Martínez CR, De Morais Freitas CHS. Sucrose concentration and pH in liquid oral pediatric medicines of long-term use for children. Rev Panam Salud Publica/Pan Am J Public Heal. 2010;27:132-7. DOI: 10.1590/s1020-49892010000200007
Hartwig AD, Ferreira LM, dos Santos Costa F, Cademartori MG, Goettems ML, Schardosim LR. Experience of dental caries and use of continuous medication in children with neuropsychomotor disorders. Pesquisa Brasileira em Odontopediatria e Clínica Integrada. 2016;16(1).
Foley M, & Akers HF. Does poverty cause dental caries? Australian dental Journal 2019, 64(1), 96-102. https://doi.org/10.1111/adj.12666
Zapata-Cortés F, García-Arróniz RG, Martínez-Arróniz F, Muñoz-Quintana G. Agrandamiento gingival crónico en paciente pediatrico: Reporte de un caso. Revista Tame. 2013;2:154-9.
Kaomongkolgit R, Tantanapornkul W, Jittapiromsak N, Ngamwannagul P, Sriaroon P. Severe Antiepileptic Drugs Induced Gingival Overgrowth in a Physically Disabled Patient. West Indian Med J. 2015; 2:65. DOI: 10.7727/wimj.2014.359
Song JH, Lee KE, Shin MK, Kim SO, Choi BJ, Choi HJ. Valproate-induced Gingival Overgrowth: A Case Report. J Korean Dis Oral Health. 2018;14:92-6.
Herrmann N, Lanctôt KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders. 2007;23(2):116-9.
Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC, et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. Journal of Child Neurology. 2007;22(6):693-9. https://doi.org/10.1177%2F0883073807303997
Alaya GQ. Efectos de los medicamentos en el apetito. Trastornos de la conducta alimentaria. 2011;(13):437-60.
Trombelli L, Farina R, Silva CO, Tatakis DN. Plaque‐induced gingivitis: Case definition and diagnostic considerations. J Clin Periodontol. 2018;45:S44-S67. https://doi.org/10.1111/jcpe.12939
Suneja B, Chopra S, Thomas AM, Pandian J. A clinical evaluation of gingival overgrowth in children on antiepileptic drug therapy. Journal of Clinical and Diagnostic Research. 2018;10(1):ZC32.
Comments
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2023 Emma Virginia Herrera-Huerta